Adobe Stock
Sun Pharmaceutical Industries has long been a standout performer in India's pharmaceutical sector. But on May 12, 2025, its stock took a noticeable dip, falling by over 3 per cent. Investors have been wondering whether this is just a market correction or if there's more to it.
Despite a recent surge in profits and market optimism, Sun Pharma's share price has slipped to Rs 1,683, down from its recent highs. This drop is largely driven by new policy changes in the US that could significantly impact the pharmaceutical sector, and Sun Pharma in particular. Let's break down what happened and why this matters.
Why did Sun Pharma's stock fall?
The immediate catalyst for the decline came from the US President's new executive order, aiming to slash prescription drug prices by up to 80 per cent. This plan, which would allow the US to negotiate drug prices based on the cheapest price available globally, threatens Indian pharma companies like Sun Pharma that rely heavily on the US market for a significant portion of their revenue. Sun Pharma's subsidiary, Taro Pharmaceutical, is a major player in the US market, and pricing cuts could hit its bottom line hard.
The fear of reduced revenue from North America caused a sharp sell-off in Sun Pharma shares, leading to the price drop on May 12. But is this a temporary pullback or a sign of longer-term struggles?
The market's reaction and Sun Pharma's current position
While the US drug pricing issue definitely triggered the decline, it's important to note that Sun Pharma is not just reliant on the US market. The company has been expanding its specialty portfolio, with significant growth in dermatology, oncology, and eye care. The company's revenue from India also continues to rise, driven by increased healthcare demand.
Despite the dip in stock price, Sun Pharma still boasts strong fundamentals. The company's latest quarterly earnings showed a 34 per cent year-on-year increase in profits. But with market volatility and regulatory changes in play, the short-term outlook has become uncertain.
Value Research Online Rating
According to Value Research Online, Sun Pharma has an overall rating of four stars. Here is how the company is rated on the following parameters:
- Quality Score: 8/10
- Growth Score: 8/10
- Valuation Score: 4/10
- Momentum Score: 8/10
What does this mean for investors?
For investors, this dip in Sun Pharma's share price may present an opportunity to buy into a solid company at a lower price. While the immediate outlook is affected by the US drug pricing policies, the long-term growth story of Sun Pharma remains intact. The company's diverse global footprint, strong product pipeline and leadership in generics and specialty drugs position it well for future growth.
Why smart investors trust expert research
Want sharper, stock-focused guidance beyond gold? Value Research Stock Advisor gives you expert-researched stock recommendations, long-term strategies and the discipline to help you build real wealth. Join thousands of successful Indian investors who trust us to guide their equity journey.
Check it out here: Value Research Stock Advisor
Disclaimer: This story was created with the assistance of artificial intelligence and is intended for informational purposes only. Please take it with a pinch of salt and do your own research or consult a financial advisor before making investment decisions.
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
